

HDFC Life Insurance

India | Insurance | Result Update



16 July 2026

Margin holds; growth search continues

HDFC Life Insurance (HDFCLIFE IN) reported APE growth of 9% YoY to INR 35.2bn – individual APE growth remains at 7% YoY and continued to lag private industry growth of 15%. Q1FY27 witnessed strong shifts in product mix, even as the HDFC Bank channel stays subdued. Retail protection remains the standout, growing 42% YoY, while non-par savings and annuities recovered sharply and ULIP demand held up. VNB rose 8.7% YoY to INR 8.8bn, with VNB margin near stable at 25.0%, down 10bp YoY), management targets VNB margin to remain at current levels as it targets individual APE to grow in line with private companies. We recommend **Buy** with a target price of INR 740.

HDFC Bank recovery in sight; proprietary channels drive growth: Bancassurance remains soft in Q1, with a channel mix at 57% and business broadly flat YoY as HDFC Bank volume continues to be weak. However, management struck a markedly more constructive tone: it characterized the earlier weakness as a temporary bout of irrational competition and it chose to sit out, noting competition has currently normalized and HDFCLIFE's counter share has largely recovered to a year ago levels. With HDFC Bank still ~47% of retail APE, normalization is the key swing factor for FY27 growth. Meanwhile, proprietary channels did the heavy lifting – agency grew 21% YoY (aided by branch expansion, with sub-24-month branches currently ~16% of agency APE), channels ex-HDFC Bank rose 17%, and proprietary channels together grew 20%+. This reinforces reduced single-distributor dependence; management reiterated an aspiration to grow at least in line with the industry, with VNB tracking APE.

Product mix turns; margin holds at ~25%: The mix shift was the quarter's real story. Non-par savings rebounded, with mix up ~220bp YoY to 18.6% (~22% of individual APE), as pricing competition eased and the rate & product backdrop improved; management flagged an exit run-rate near 25%. Annuities more than doubled YoY to ~9% of APE, led by variable annuity (AGNI), currently ~half of annuity sales at above-average margin. ULIP remains strong (mix 37.2%, up 450bp YoY) and retail protection extended its run, up 42% YoY (mix was up 160bp to 6.8%), although H2 growth should moderate on high base. The main drag was par, which nearly halved YoY off an elevated Q1FY26 base. VNB margin held at 25.0% with the residual GST drag was down to ~60bp and set to neutralize in the upcoming quarters; management remains growth-first, opting to reinvest mix-led margin upside rather than maximize it in the P&L. We build in ~11.8% APE CAGR and ~15.1% VNB CAGR during FY26-29E.

Recommend Buy with a TP of INR 740: We value the franchise on appraisal value approach; we recommend **Buy** with a TP of INR 740 based on 1.9x March 2028E EVPS of INR 386, implying ~30% upside to the CMP. We believe HDFCLIFE has faced increased competition in its non-par-guaranteed savings segment; as this intensity eases driven by HDFCLIFE improving the IRR for the products, we expect the product mix to become more favorable aiding in margin improvement, alongside growth converging towards industry levels. Further, we believe any material rationalization in first-year commissions by the IRDAI will pose a downside risk to our estimates.

Key financials

YE March (INR mn)	FY25	FY26	FY27E	FY28E	FY29E
APE (INR mn)	154,790	166,410	185,506	207,647	232,474
YoY (%)	16.5	7.5	11.5	11.9	12.0
VNB (INR mn)	39,620	40,340	46,880	53,576	61,570
VNB margin (%)	25.6	24.2	25.3	25.8	26.5
VNB per share (INR)	18.4	18.8	21.8	24.9	28.6
EVOP per share (INR)	36.8	38.8	45.0	52.0	59.8
EV per share (INR)	257.8	288.9	338.0	389.1	448.0
Operating RoEV (%)	16.7	15.0	15.6	15.4	15.4
P/VNB (x)	30.9	30.3	26.1	22.8	19.9
P/EVOP (x)	15.4	14.7	12.7	10.9	9.5
P/EV (x)	2.2	2.0	1.7	1.5	1.3

Note: Pricing as on 15 July 2026; Source: Company, Elara Securities Estimate

Rating: **Buy**

Target Price: **INR 740**

Upside: **30%**

CMP: **INR 569**

As on 15 July 2026

Key data

Bloomberg	HDFCLIFE IN
Reuters Code	HDFLNS
Shares outstanding (mn)	2,172
Market cap (INR bn/USD mn)	1,236/12,835
EV (INR bn/USD mn)	1,247/12,950
ADTV 3M (INR mn/USD mn)	3,329/35
52 week high/low	815/543
Free float (%)	50

Note: as on 15 July 2026; Source: Bloomberg

Price chart



Source: Bloomberg

	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26
Shareholding (%)				
Promoter	50.3	50.3	50.2	50.2
% Pledge	0.0	0.0	0.0	0.0
FII	24.8	24.8	24.3	22.5
DII	14.6	14.6	15.2	17.3
Others	10.4	10.3	10.3	10.0

Source: BSE

Price performance (%)	3M	6M	12M
Nifty	(0.5)	(6.3)	(4.5)
HDFC Life Insurance	(11.2)	(23.5)	(24.9)
NSE Mid-cap	3.3	0.4	1.2
NSE Small-cap	11.7	11.7	0.6

Source: Bloomberg

Shobhit Sharma

Non-Lending Financials

+912261648587
shobhit.sharma@elaracapital.com

Associate
Devarshi Raj
devarshi.raj@elaracapital.com



Financials (YE March)

Movement in EV (INR mn)	FY25	FY26	FY27E	FY28E	FY29E
Opening EV	474,700	554,200	621,400	726,878	836,789
Assumption changes	-	-	-	-	-
Value of New Business	39,620	40,340	46,880	53,576	61,570
Discount unwind	38,400	43,600	49,797	58,235	67,028
Operating Variance	1,200	(600)	-	-	-
Operating EV Earnings	79,220	83,340	96,678	111,811	128,598
Economic Variance	3,600	(17,900)	10,700	-	-
Total EV Earnings	82,820	65,440	107,378	111,811	128,598
Closing EV	554,320	621,340	726,878	836,789	963,487
RoEV Tree	FY25	FY26	FY27E	FY28E	FY29E
Unwind as % of opening EV	8.1	7.9	8.0	8.0	8.0
VNB as % of opening EV	8.3	7.3	7.5	7.4	7.4
Operating variances as % of opening EV	0.3	(0.1)	-	-	-
Assumption changes as % of opening EV	-	-	-	-	-
Operating RoEV (%)	16.7	15.0	15.6	15.4	15.4
Margin Profile	FY25	FY26	FY27E	FY28E	FY29E
VNB (INR mn)	39,620	40,340	46,880	53,576	61,570
YoY %	13.2	1.8	16.2	14.3	14.9
APE (INR mn)	154,790	166,410	185,506	207,647	232,474
YoY %	16.5	7.5	11.5	11.9	12.0
VNB margin (%)	25.6	24.2	25.3	25.8	26.5
APE by segment - mix (%)	FY25	FY26	FY27E	FY28E	FY29E
Savings					
Non-Linked	44.9	37.8	33.6	39.0	39.2
Unit Linked	34.3	38.7	38.9	32.9	32.4
Annuity	4.4	5.1	8.8	9.1	9.4
Group Savings	5.4	4.5	4.7	4.5	4.4
Savings APE	89.0	86.1	86.0	85.5	85.3
Retail	4.4	6.3	7.0	7.7	8.2
Group	6.6	7.6	7.0	6.8	6.5
Protection APE	11.0	13.9	14.0	14.5	14.7
Profit & Loss Account (INR mn)	FY25	FY26	FY27E	FY28E	FY29E
Gross Premium Written	710,647	794,536	895,091	1,009,864	1,140,857
Investment income	262,283	205,225	258,790	287,842	320,673
Commission paid	78,394	91,234	114,923	140,517	167,937
Expenses	62,372	77,145	88,716	102,024	117,327
Claims/benefits paid	393,459	383,234	421,665	455,124	491,237
Change in actuarial liability	415,156	424,335	497,435	571,378	645,147
Profit after tax	9,063	2,430	19,172	15,158	24,625
Balance Sheet (INR mn)	FY25	FY26	FY27E	FY28E	FY29E
Sources of funds					
Shareholder's equity	161,256	176,961	221,764	265,386	323,682
Borrowings	-	-	-	-	-
Fair value change - Policyholders	-	-	-	-	-
Revaluation Reserves	-	-	-	-	-
Policyholder's liabilities	3,221,829	3,608,994	3,920,919	4,361,073	4,858,498
Funds for Future Appropriation	12,256	4,064	5,006	6,040	7,853
Current Liabilities & Provisions	-	-	-	-	-
Total Liabilities & Equity	3,395,342	3,790,018	4,147,689	4,632,499	5,190,033
Application of capital					
Shareholder's investments	183,863	200,549	212,581	225,336	238,856
Policyholder's investments	2,162,671	2,499,515	2,803,532	3,232,504	3,731,933
Linked investments	1,016,282	1,051,916	1,093,993	1,137,753	1,183,263
Other Assets	32,526	38,039	37,582	36,906	35,981
Total Assets	3,395,342	3,790,018	4,147,689	4,632,499	5,190,033
Valuations	FY25	FY26	FY27E	FY28E	FY29E
P/EV (x)	2.2	2.0	1.7	1.5	1.3
P/VNB (x)	30.9	30.3	26.1	22.8	19.9
P/EVOP (x)	15.4	14.7	12.7	10.9	9.5
VNB multiple (x)	16.9	14.9	10.6	7.2	4.2

Note: Pricing as on 15 July 2026; Source: Company, Elara Securities Estimate

Exhibit 1: Quarterly financials

Particulars	Units	Q1FY26	Q1FY27	Change (%)	FY24	FY25	FY26
RNB	INR mn	30,224	32,916	8.9	129,629	150,316	161,518
IRNB	INR mn	27,172	29,223	7.5	113,764	133,637	143,884
APE	INR mn	32,250	35,150	9.0	132,900	154,790	166,410
VNB	INR mn	8,090	8,790	8.7	35,000	39,620	40,340
VNB Margin	%	25.1	25.0	-0.1	26.3	25.6	24.2
Product Mix							
PAR	%	27.6	12.7	-14.9	19.9	16.7	22.0
NPS	%	16.4	18.6	2.2	26.0	28.2	15.8
NPT	%	5.2	6.8	1.6	4.3	4.4	6.3
ANN	%	4.3	9.3	5	6.1	4.4	5.1
ULI	%	32.7	37.2	4.4	30.3	34.3	38.7
Group Fund	%	5.1	6.3	1.2	4.7	5.4	4.5
Group Term	%	8.8	9.2	0.4	8.7	6.6	7.6
APE/RNB	%	106.7	106.8	0.1	102.5	103.0	103.0
Total Cost/APE	%	101.1	110.9	9.8	91.5	90.9	101.2
Total cost excluding renewal commission/APE	%	97.0	105.9	8.9	87.6	87.1	97.1
Total cost exc Comm/APE	%	46.8	50.8	4	51.9	40.3	46.4
Total cost excluding renewal commission/Ind APE	%	112.7	125.4	12.7	101.1	99.0	110.4
Total cost excluding renewal commission/Weighted APE	%	71.6	80.8	9.2	60.8	60.1	70.5

Source: Company, Elara Securities Research

Conference call key takeaways

HDFC Bank recovery becoming increasingly visible

- ▶ Management's confidence around the HDFC Bank channel was noticeably stronger than in the previous quarters.
- ▶ While business through HDFC Bank remains subdued during Q1 because of weak bank-level volume, management says competition has normalized and HDFCLIFE 's counter share has recovered to levels seen a year ago.
- ▶ Management emphasized the issue was never structural but rather a temporary period of irrational competition that it chose not to participate in. As HDFC Bank's own growth normalizes, it expects the channel to progressively contribute meaningfully for the rest of FY27.
- ▶ Importantly, HDFC Bank still contributes 47% of retail APE, making the recovery in this channel one of the key swing factors for FY27 growth.

Agency channel continues to emerge as the primary growth engine

- ▶ Agency remains the strongest performing proprietary channel, growing 21% YoY, comfortably ahead of company growth.
- ▶ Management attributed this to investments made in the past two years through:
 - ▶ Branch expansion
 - ▶ Agent productivity
 - ▶ Training
 - ▶ Deeper penetration in Tier II & III markets
- ▶ New branches opened in the last 24 months currently contribute roughly 16% of agency APE vs high single digits in the past year, indicating that operating leverage from these investments is beginning to materialize.

- ▶ Another encouraging trend is the improving business mix within the agency, with protection and annuity contributing a significantly larger share of sales, supporting profitability alongside growth.

Growth remains broad-based despite temporary HDFC Bank weakness

- ▶ Management says channels excluding HDFC Bank grew 17%, while proprietary channels delivered 20%+ growth.
- ▶ This reinforces management's view the company is no longer dependent on a single distributor for growth and that the broader distribution franchise remains healthy.
- ▶ Accordingly, management reiterated its aspiration to grow at least in line with the industry while retaining VNB growth broadly in line with APE growth during FY27.

Non-par business recovering as competitive intensity eases

- ▶ Management believes non-par is finally showing signs of recovery after a difficult FY26.
- ▶ Improvement has been driven by several factors:
 - ▶ Normalization of competitive pricing
 - ▶ Better interest-rate environment
 - ▶ Improving customer preference toward guaranteed products
 - ▶ Calibrated product repositioning.
- ▶ Non-par mix improved to 22% during Q1 and is already running at ~25% on an exit basis, with management expecting gradual improvement for the rest the year.
- ▶ Unlike earlier quarters, management sounded more constructive on the outlook for guaranteed savings products.

Variable annuity emerging as a meaningful growth opportunity

- ▶ Variable annuity has quickly become one of the most encouraging product developments.
- ▶ The category currently accounts for nearly half of annuity sales, with management indicating:
 - ▶ Margins are above the company average
 - ▶ Customer acceptance has exceeded expectations
 - ▶ Further product innovation is likely as regulations evolve
- ▶ Management believes variable annuity materially expands the addressable retirement market by appealing to younger customers willing to accept limited investment variability in exchange for higher long-term retirement income.

Margin philosophy remains growth-first

- ▶ Management spent considerable time explaining why headline VNB margin have yet to expand vs peers despite improvement in product mix.
- ▶ According to management, three external events interrupted the natural margin expansion cycle:
 - ▶ Taxation changes on high-ticket policies
 - ▶ Surrender value regulations
 - ▶ GST changes.

- ▶ Excluding these regulatory disruptions, management believes underlying economics have steadily improved.
- ▶ It expects VNB margin to remain around the current levels of ~25%, with any underlying margin improvement likely to be reinvested into growth rather than maximized in the P&L.
- ▶ The remaining GST impact has reduced to roughly 60 bps, which management expects to offset in the upcoming quarters.


Protection remains a structural growth driver

- ▶ Retail protection continues to significantly outperform the overall business, growing 42% YoY.
- ▶ Management expects growth rates to moderate during H2 because of high base, but it reiterated protection remains one of its highest strategic priorities.
- ▶ Growth continues to be supported by:
 - ▶ Agency
 - ▶ Non-bank alliances
 - ▶ Aggregators
 - ▶ Improving credit life demand
- ▶ Management remains focused on increasing protection penetration rather than maximizing short-term growth percentages.


Capital position comfortable despite higher protection mix

- ▶ Following the preferential capital raise, solvency improved to 185%, providing adequate capacity to support business growth.
- ▶ Management remains comfortable with the current capital position while awaiting implementation of the Risk-Based Capital Framework.


Exhibit 2: APE grows 9.0% YoY to INR 35.2bn




Source: Company, Elara Securities Research

Exhibit 3: VNB rises 8.7% YoY to INR 8.8bn



Source: Company, Elara Securities Research

Exhibit 4: VNB margin holds at 25.0%



Note: Total cost excludes renewal commission; Source: Company, Elara Securities Research

Exhibit 5: ULIP and non-par savings gain share as par slumps


Source: Company, Elara Securities Research

Exhibit 6: Bancassurance eases to 57% as agency share rises


Source: Company, Elara Securities Research

Exhibit 7: NB commission and opex ratios both rise YoY driven by favorable product mix shift


Source: Company, Elara Securities Research

Exhibit 8: Valuation


Required Return (%)	12.0
Terminal growth (%)	5.0
FY27E ROEV (%)	17.3
FY27E EVPS (INR)	333.9
FY28E EVPS (INR)	386.0
P/EV (x)	1.9
TP (INR)	740

Source: Elara Securities Estimate

Key Risks

- ▶ IRDAI commission rationalization could adversely impact earnings and profitability.
- ▶ Delayed recovery in HDFC Bank channel could keep APE growth below industry levels.
- ▶ Higher-than-expected competition in non-par savings could weigh on product mix, margins, and growth.

Coverage History



Date	Rating	Target Price (INR)	Closing Price (INR)
21-Jan-2022	Buy	880	641
26-Apr-2022	Buy	700	550
19-Jul-2022	Buy	740	536
15-Oct-2024	Accumulate	810	714
15-Jan-2025	Accumulate	700	594
17-Apr-2025	Buy	870	720
15-Jul-2025	Buy	890	757
15-Oct-2025	Accumulate	890	761
14-Jan-2026	Buy	890	743
16-Apr-2026	Buy	760	632
15-Jul-2026*	Buy	740	569

*AC=Analyst change

Guide to Research Rating

BUY (B)	Absolute Return >+20%
ACCUMULATE (A)	Absolute Return +5% to +20%
REDUCE (R)	Absolute Return -5% to +5%
SELL (S)	Absolute Return < -5%

Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the “Recipient”) only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE] and BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Artificial Intelligence (AI) tools may have been used only for compilation or collating publicly available research data or internally generated research data during the information gathering and/or summarizing the final report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Disclosures for U.S. Investors

Rule 15a6 Disclosure: This research report ("Report") was prepared, approved, published, and distributed by Elara Securities (India) Private Limited a company located outside of the United States (the "Foreign Counterparty"). Avior Capital Markets US LLC ("Avior US"), a US registered broker-dealer, distributes this Report in the US on behalf of the Foreign Counterparty. Only major U.S. institutional investors (as defined in Rule 15a-6 under the US Securities Exchange Act of 1934 (the "Exchange Act")) may receive this Report under the exemption in Rule 15a-6. A US institutional investor must effect any transaction in the securities described in this Report through Avior US.

Neither the Report nor any analyst who prepared or approved the Report is subject to US legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other US regulatory requirements concerning research reports or research analysts. The Foreign Counterparty is not a registered broker-dealer under the Exchange Act nor is it a member of the Financial Industry Regulatory Authority, Inc., or any other US self-regulatory organisation.

Disclosures on Subject Companies: Analysts of the Foreign Counterparty produced this material solely for informational purposes and the use of the intended recipient. No person may reproduce, this Report under any circumstances. No person may copy or make this Report available to any other person other than the intended recipient.

Avior US distributes this Report in the United States of America. The Foreign Counterparty distributes this Report elsewhere in the world. This document is not an offer, or invitation by or on behalf of Avior US, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Avior US and the Foreign Counterparty and their affiliates obtained the information contained herein from published information and other sources, which Avior US and the Foreign Counterparty and their affiliates reasonably consider to be reliable.

Avior US and the Foreign Counterparty accept no liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are valid as of the date of this document. Avior US assumes responsibility for the Report content with regards to research distributed in the US.

Neither Avior US nor the Foreign Counterparty has managed or co-managed a public offering of securities for the subject company in the past 12 months, have not received compensation for investment banking services from the subject company in the past 12 months and do not expect to receive and does not intend to seek compensation for investment banking services from the subject company in the next three months. Avior US and the Foreign Counterparty have not owned any class of equity securities of the subject company. There are no other actual, material conflicts of interest of Avior US and the Foreign Counterparty at the time of the publication of this Report. As of the publication of this Report, Avior US nor the Foreign Counterparty makes a market in the subject securities.

Avior US and its affiliates, to the fullest extent permissible by law, accept no liability of any nature whatsoever for any claims, damages or losses arising from, or in connection with, the contents of this Report or the use, reliance, publication, distribution, dissemination, disclosure, alteration or reproduction of this Report, or any views or recommendations recorded therein.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Subject to the applicable laws, all transactions should be executed through Avior US. Aside from within this Report, important conflict disclosures can also be found at <https://aviorcapital.us/us-regulatory-disclosures/> and Investors are strongly encouraged to review this information before investing.

Additional Disclaimer for UK Investors

Note that Elara Securities (India) Private Limited ("Foreign Counterparty") has concluded a MiFID II research intermediary agreement with Avior Capital Markets International Limited ("Avior UK"), regulated by the Financial Conduct Authority (FRN: 191074), pursuant to which Avior UK distributes the Foreign Counterparty's research in the UK, in return for which the Foreign Counterparty pays Avior UK a percentage of the income received in relation to such research. This research report including any recommendations recorded therein ("Report") have been prepared by the Foreign Counterparty, and not by Avior UK.

The Report: (a) has been objectively prepared from public sources which are believed to be reliable and therefore constitutes independent investment research and is presented as such; and (b) may only be distributed to, and relied on by, qualifying investors, who are permitted to receive same in the UK.

Securities, money market instruments, strategies, financial or investment instruments mentioned in this Report may not be suitable for all investors. The information and opinions provided in this Report do not constitute a personal recommendation/investment advice and take no account of the investor's individual circumstances. Investors should consider this Report as only a single factor in making any investment decisions and, if appropriate, should seek advice from an investment advisor. This Report is not an offer, or invitation by or on behalf of Avior UK, the Foreign Counterparty, their affiliates, or any other person, to buy or sell any security.

Save as disclosed otherwise, the Foreign Counterparty's relationship with Avior UK is not reasonably expected to impair the objective presentation of the recommendations in the Report, including any interests or conflicts of interest concerning any financial instruments or the issuers to which the recommendations, directly or indirectly, relate. The Report is deemed to be first disseminated at the date and time recorded on the relevant distribution platform, data network or email (as applicable), and which information is available on request. A list of the Foreign Counterparty's research reports disseminated in the UK over the past 12 months is also available on request.

Avior UK does not assume any responsibility or liability of any nature whatsoever arising from or in connection with the content, use, reliance or dissemination of the Report or any recommendation in respect thereof and disclaims any such liability.

Certification by Each of the Authors of this Report

The analyst(s) (singular includes plural) ("Analyst") certifies that the views expressed in this Report are an accurate representation of the Analyst's personal opinions on the stock or sector as covered and reported on by the Analyst hereinabove. The Analyst furthermore certifies that no part of the Analyst's compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views as expressed in this document. The Analyst is principally responsible for the preparation of this Report and does not have any material conflict of interest at the time of publication of this Report. The Analyst(s) has not served as an officer, director or employee of the subject company in the last 12-month period ending on the last day of the month immediately preceding the date of publication of the Report.

Analyst Certification: In connection with the companies or securities that; each analyst identified in this Report certifies that: The views expressed on the subject companies and securities in this Report reflect their personal views. No part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this Report.

Note that:

- (i) The Foreign Counterparty is the employer of the research analyst(s) responsible for the content of this Report, and
- (ii) Research analysts preparing this Report are resident outside the United States and are not associated persons of any US regulated broker-dealer. Therefore, the analyst(s) are not subject to supervision by a US broker-dealer and are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with US rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

Avior Capital Markets US, LLC is a FINRA registered broker-dealer (CRD # 172595) formed for that purpose in the State of Delaware with its principal office at 45 Rockefeller Plaza, Suite 2335, New York, New York 10111.

Avior Capital Markets International Limited is regulated by the Financial Conduct Authority (FRN: 191074), with its principal office at 10 South Street, Elgin, Scotland IV30 1LE.

Elara Securities (India) Private Limited is a SEBI-registered Research Analyst (Regn. No.: INH000000933), Stock Broker (Regn. No.: INZ000238236) and Depository Participant (Regn. No.: IN-DP-370-2018). Its registered address is One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India

India Elara Securities (India) Private Limited One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500	Europe Elara Capital Plc. 6th Floor, The Grove, 248A Marylebone Road, London, NW1 6JZ, United Kingdom Tel : +44 20 7486 9733	USA Elara Securities Inc. 950 Third Avenue, Suite 1900 New York, NY 10022 United States Tel: +1 212 430 5870 Fax: +1 212 208 2501	Asia / Pacific Elara Capital (Singapore) Pte.Ltd. One Marina Boulevard, Level 20, Singapore 018989 Tel : +65 6978 4047
---	--	--	---



Managing Director

Harendra Kumar | harendra.kumar@elaracapital.com | +91 22 6164 8571



Head of Sales

Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544



Head of Research


Dr Bino Pathiparampil | bino.pathiparampil@elaracapital.com | +91 22 6164 8572



Deputy Head of Research & Strategist

Garima Kapoor | garima.kapoor@elaracapital.com | +91 22 6164 8527

Sales Team



India & UK

Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544



India

Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543
Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558
Himani Sanghavi - himani.sanghavi@elaracapital.com - +91 22 6164 8586
Pooja Soni - pooja.soni@elaracapital.com - +91 22 6164 8558



India, APAC & Australia

Sudhanshu Rajpal - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508
Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541
Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567
Suyash Maheshwari - suyash.maheshwari@elaracapital.com - +91 22 4204 8698



India & US

Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570



Corporate Access, Conference & Events

Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520
Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595

By clicking this link, you acknowledge and agree to the [Terms and Conditions of Research Services](#)
Access our reports on Bloomberg: Type **RESP ESEC <GO>**

Also available on **Thomson & Reuters**

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500
CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933
Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ000238236
Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018
Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel. +91 22 6164 8509
Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapital.com - Tel. +91 22 6164 8509